Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbbVie Inc (ABBV) vs Avient Corporation (AVNT) Price & Performance

AbbVie IncTrade
Avient CorporationTrade

Price performance (Past 24H)

Key statistics

AbbVie Inc vs Avient Corporation — how do they compare? AbbVie Inc trades at $250 (market cap $438.19B), while Avient Corporation trades at $45.51 (market cap $4.19B). The key difference: AbbVie Inc is far larger — about 104.6× Avient Corporation's market cap, and AbbVie Inc pays the higher dividend (2.79%). Which is the better fit depends on your goals.

ABBVAVNT
Market Cap
$438.19B$4.19B
Sector
HealthTechnology
52-Week High
$263.58$45.69
52-Week Low
$197.38$27.48
Enterprise Value
$502.45B$5.64B
Dividend Yield
2.79%2.41%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbbVie Inc

AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.

Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.

Avient Corporation

Avient Corporation (AVNT) trades at $45.69, up 7.13% with strong technical momentum. The stock shows consistent earnings beats with Q2 2026 EPS of $0.96 exceeding expectations by $0.07. Analyst consensus remains bullish with a $49.00 price target and 60% buy ratings. Recent quarterly dividend of $0.275 per share demonstrates shareholder returns while maintaining operational strength with $299M operating cash flow in 2026.

Outlook remains positive with improved full-year guidance and 20% adjusted EPS growth. Key risks include competitive pressures in chemical sector and potential margin compression. Upside potential exists toward $49-50 resistance zone, supported by strong fundamentals and institutional confidence in management's execution capabilities.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AbbVie Inc

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

Read more on ABBV

About Avient Corporation

Avient Corporation is a global leader in specialized and sustainable material solutions. Formed from the legacy of PolyOne and Clariant’s masterbatch business, it provides highly engineered polymer formulations, color systems, and advanced composites that enhance the performance and sustainability of products in industries like healthcare, defense, and consumer packaging.

Read more on AVNT